Effect of nitric oxide synthase (NOS) activity on Lenvatinib for unresectable hepatocellular carcinoma
Not Applicable
Recruiting
- Conditions
- nresectable hepatocellular carcinomaHepatocellular CarcinomasD006528
- Registration Number
- JPRN-jRCT1030210283
- Lead Sponsor
- Hidaka Hisashi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients with hepatocellular carcinoma who received lenvatinib between October 1, 2018 and September 30, 2020.
Patients enrolled in the Multicenter Study of Factors Contributing to the Efficacy and Survival of Lenvatinib in Hepatocellular Carcinoma.
Patients who have arbitrarily stored serum before and after treatment.
Exclusion Criteria
Patients who are considered unsuitable for participation in this study by the principal investigator and sub-investigators
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method